ZVSA

ZyVersa is a pre-revenue, clinical-stage biopharma with two unapproved candidates (VAR 200 for FSGS, IC 100 for inflammatory disease) and, by its own filing, 'no products approved for commercial sale' and 'never been profitable.' The numbers describe a company at the end of its runway, not a speculative early bet: FY2025 cash and equivalents of just $102K against $12.7M of current liabilities and a total-assets figure of $348K (down 98.3% YoY). Stockholders' equity is negative $12.4M (liabilities/equity −1.03x), and the accumulated deficit is ~$138M — the MD&A itself flags 'net losses and negative cash flows for the foreseeable future' and a need for financing that 'may not be available to us on acceptable terms, or at all.' This is textbook going-concern territory.

The structural damage goes beyond the balance sheet. Effective October 6, 2025 the stock was delisted from Nasdaq (the Hearings Panel denied continued listing) and now quotes on OTCQB — the filing warns of 'substantially less liquidity,' difficulty selling shares 'in an orderly manner or at all,' and reduced analyst coverage. In September 2025 management wrote off its entire in-process R&D intangible with an $18.6M impairment after judging the carrying value unrecoverable — a signal that the company's own pipeline valuation has collapsed. Shares outstanding rose 215% YoY to 8.10M as operations were financed purely by selling equity ('to date, we have financed our operations through the sale of our equity securities'), so any further capital raise means severe dilution from an already broken share base; the −$4.18 diluted EPS reflects that.